Pyxis Oncology(US:PYXS)2022-06-09 19:37Company Highlights - Pyxis Oncology has a strong balance sheet with approximately $231 million in cash as of May 13, 2022[7] - The company's IO and ADC programs are expected to deliver multiple potential catalysts over the next 12-24 months[7] Pipeline Development - The company plans to submit IND applications for PYX-106 (Anti-Siglec-15) and PYX-201 (Anti-EDB) in the second half of 2022[25] - Pyxis Oncology is targeting IND submission for PYX-102 (Anti-KLRG1) and PYX-203 (Anti-CD123) in the second half of 2023[25] - A program update for PYX-202 (Anti-DLK1) is expected in mid-2022[25] Drug Target and Mechanism - PYX-106 demonstrates 6-fold higher affinity to human Siglec-15 than benchmark in development[27] - EDB mRNA expression is upregulated in tumor over normal tissue in several cancer indications[64] - Anti-DLK1 (PYX-202) is designed to bind a rapidly internalized target with tumor-selective beta-glucuronide linker to mitigate known MMAE toxicities[76] Market and Potential - Pyxis Oncology estimates a potential U S peak sales of over $5 billion across its pipeline[99] - The total incidence of Non-Small Cell Lung Cancer in the U S is 200,000[41] - The total incidence of Head and Neck Cancer in the U S is 60,000[41]